BRD2 and benign neoplasm: Even though we compared tumor tissue and NAT from the same patients to minimize variable factors, the holistic immune signature of NAT was different from tissue from healthy volunteer or patients with benign tumor (as immune phenotypes are affected by the presence of tumors) (44).